Nova Max Creat eGFR Monitoring System— 510(k) K251281
Substantially EquivalentNova Biomedical Corporation
FDA 510(k) clearance K251281 for Nova Max Creat eGFR Monitoring System, Substantially Equivalent on 2026-01-21. Applicant: Nova Biomedical Corporation. Device class: 2.
Clearance details
- Applicant
- Nova Biomedical Corporation
- Product code
- Code SHB
- Device class
- Class 2
- Regulation
- 21 CFR 862.1225
- Advisory panel
- Clinical Chemistry
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Walham, MA, US
More clearances from Nova Biomedical Corporation
view allData sourced from openFDA. This site is unofficial and independent of the FDA.